Rhenman & Partners Asset Management’s Coherus Oncology, Inc. Common Stock CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-290,000
| Closed | -$5.88M | – | 95 |
|
|
2019
Q3 | $5.88M | Sell |
290,000
-100,000
| -26% | -$2.03M | 0.74% | 51 |
|
|
2019
Q2 | $8.62M | Sell |
390,000
-61,131
| -14% | -$1.35M | 0.95% | 44 |
|
|
2019
Q1 | $6.15M | Buy |
451,131
+130,000
| +40% | +$1.77M | 0.72% | 55 |
|
|
2018
Q4 | $2.91M | Sell |
321,131
-10,000
| -3% | -$90.5K | 0.33% | 66 |
|
|
2018
Q3 | $5.46M | Sell |
331,131
-18,869
| -5% | -$311K | 0.55% | 62 |
|
|
2018
Q2 | $4.9M | Hold |
350,000
| – | – | 0.5% | 60 |
|
|
2018
Q1 | $3.87M | Hold |
350,000
| – | – | 0.48% | 60 |
|
|
2017
Q4 | $3.08M | Buy |
350,000
+170,000
| +94% | +$1.5M | 0.42% | 66 |
|
|
2017
Q3 | $2.4M | Buy |
180,000
+11,128
| +7% | +$149K | 0.31% | 73 |
|
|
2017
Q2 | $2.42M | Buy |
168,872
+57,515
| +52% | +$825K | 0.35% | 75 |
|
|
2017
Q1 | $2.36M | Hold |
111,357
| – | – | 0.37% | 77 |
|
|
2016
Q4 | $3.14M | Sell |
111,357
-20,000
| -15% | -$563K | 0.6% | 62 |
|
|
2016
Q3 | $3.52M | Hold |
131,357
| – | – | 0.56% | 64 |
|
|
2016
Q2 | $2.22M | Buy |
+131,357
| New | +$2.22M | 0.39% | 70 |
|